Posted by Michael Wonder on 03 May 2018
For expensive new drugs, biopharma should make money-back guarantees mandatory
2 May 2018 - In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of the Memorial Sloan Kettering Cancer Center discuss the high cost of drugs, particularly the newly introduced gene therapies and biologicals, and the emerging new policy ideas designed to cope with the impact of these drugs on the healthcare system.
The authors focus on three general themes: aligning drug price with drug benefits; altering the mechanism of drug payment; and aligning demand with value.
All of these approaches merit discussion as we all grapple with the issue for paying for new drugs that can cure deadly diseases.
